173 related articles for article (PubMed ID: 30883140)
21. Chemokine receptor - Directed imaging and therapy.
Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
[TBL] [Abstract][Full Text] [Related]
22. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
Vag T; Gerngross C; Herhaus P; Eiber M; Philipp-Abbrederis K; Graner FP; Ettl J; Keller U; Wester HJ; Schwaiger M
J Nucl Med; 2016 May; 57(5):741-6. PubMed ID: 26769866
[TBL] [Abstract][Full Text] [Related]
23. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.
Luker KE; Lewin SA; Mihalko LA; Schmidt BT; Winkler JS; Coggins NL; Thomas DG; Luker GD
Oncogene; 2012 Nov; 31(45):4750-8. PubMed ID: 22266857
[TBL] [Abstract][Full Text] [Related]
24. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.
Nimmagadda S; Pullambhatla M; Stone K; Green G; Bhujwalla ZM; Pomper MG
Cancer Res; 2010 May; 70(10):3935-44. PubMed ID: 20460522
[TBL] [Abstract][Full Text] [Related]
25. N-[
Hartimath SV; Khayum MA; van Waarde A; Dierckx RAJO; de Vries EFJ
Mol Imaging Biol; 2017 Aug; 19(4):570-577. PubMed ID: 27896627
[TBL] [Abstract][Full Text] [Related]
26. Development of a novel
Zhang X; You L; Chen S; Gao M; Guo Z; Du J; Lu J; Zhang X
J Labelled Comp Radiopharm; 2018 May; 61(5):438-446. PubMed ID: 29370457
[TBL] [Abstract][Full Text] [Related]
27. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.
Lesniak WG; Sikorska E; Shallal H; Behnam Azad B; Lisok A; Pullambhatla M; Pomper MG; Nimmagadda S
Mol Pharm; 2015 Mar; 12(3):941-53. PubMed ID: 25590535
[TBL] [Abstract][Full Text] [Related]
28. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.
Oum YH; Shetty D; Yoon Y; Liang Z; Voll RJ; Goodman MM; Shim H
Bioorg Med Chem; 2020 Jan; 28(2):115240. PubMed ID: 31843463
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and Bioevaluation of Novel [
Yang X; Wang F; Zhu H; Yang Z; Chu T
Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
[TBL] [Abstract][Full Text] [Related]
30. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway.
Gao XL; Zheng M; Wang HF; Dai LL; Yu XH; Yang X; Pang X; Li L; Zhang M; Wang SS; Wu JB; Tang YJ; Liang XH; Tang YL
BMC Cancer; 2019 Jul; 19(1):743. PubMed ID: 31357956
[TBL] [Abstract][Full Text] [Related]
31. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
32. Al[18F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression.
Yan X; Niu G; Wang Z; Yang X; Kiesewetter DO; Jacobson O; Shen B; Chen X
Mol Imaging Biol; 2016 Feb; 18(1):135-42. PubMed ID: 26126597
[TBL] [Abstract][Full Text] [Related]
33. OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma.
Yang W; Wang C; Lin Y; Liu Q; Yu LX; Tang L; Yan HX; Fu J; Chen Y; Zhang HL; Tang L; Zheng LY; He YQ; Li YQ; Wu FQ; Zou SS; Li Z; Wu MC; Feng GS; Wang HY
J Hepatol; 2012 Sep; 57(3):613-20. PubMed ID: 22612999
[TBL] [Abstract][Full Text] [Related]
34. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.
Dillenburg-Pilla P; Patel V; Mikelis CM; Zárate-Bladés CR; Doçi CL; Amornphimoltham P; Wang Z; Martin D; Leelahavanichkul K; Dorsam RT; Masedunskas A; Weigert R; Molinolo AA; Gutkind JS
FASEB J; 2015 Mar; 29(3):1056-68. PubMed ID: 25466898
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET.
Hofmann S; Maschauer S; Kuwert T; Beck-Sickinger AG; Prante O
Mol Pharm; 2015 Apr; 12(4):1121-30. PubMed ID: 25748228
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Evaluation of [
Peng T; Wang X; Li Z; Bi L; Gao J; Yang M; Wang Y; Yao X; Shan H; Jin H
Mol Pharm; 2021 Sep; 18(9):3638-3648. PubMed ID: 34424706
[TBL] [Abstract][Full Text] [Related]
38. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
39. In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.
Lesniak WG; Aboye T; Chatterjee S; Camarero JA; Nimmagadda S
Chemistry; 2017 Oct; 23(58):14469-14475. PubMed ID: 28771849
[TBL] [Abstract][Full Text] [Related]
40. Improvement of CXCR4 tracer specificity for PET imaging.
Jacobson O; Weiss ID; Szajek LP; Niu G; Ma Y; Kiesewetter DO; Peled A; Eden HS; Farber JM; Chen X
J Control Release; 2012 Jan; 157(2):216-23. PubMed ID: 21964282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
